FDA to fast-track reviews of 3 psychedelic drugs
Digest more
President Trump issued an executive order to fast-track psychedelic therapies like ibogaine to treat PTSD and other mental ...
After an executive order, the FDA announced it would prioritize the study of some psychedelic drugs for therapeutic use.
Psychedelics are gaining the attention of the federal government as a potential treatment for complex mental health conditions, but healthcare leaders remain divided on their readiness for broader ...
Psychedelic therapy shows promise, but what makes its effects last? The answer may lie not in the drug, but in what happens ...
Researchers are investigating the use of psilocybin as a potential anti-aging therapy. Jon Cartwright/Getty Images Psilocybin is a chemical that is found in a wide variety of mushrooms. Also known as ...
A new study suggests that virtual reality experiences designed to mimic psychedelic visual effects could safely boost creativity and flexibility in thinking -- without the use of drugs.
Psychedelic stocks rose amid reports President Trump plans to sign an executive order to boost research into ibogaine, a ...
National Priority Vouchers aim to shorten FDA review from ~10–12 months to ~1–2 months using collaborative multidisciplinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results